Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib, Thalidomide and Dexamethasone in NDMM
NCT03608501Phase 2Withdrawn
- Sponsor
- Takeda
- Start
- Sep 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ixazomib in multiple myeloma (MM), sponsored by Takeda. Primary endpoint: Overall Response Rate During Induction at 9 months. Planned start Sep 2019; status: withdrawn.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03608501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03608501.